i) Imagine you are the Entrepreneur and CEO of Nucleon Inc. Make recommendations for Phase I, II, and III clinical trials to the shareholders and justify your recommendations. Remember: As a major stockholder, I may want to know about the financial implications (e.g., NPV) of the choices, the impact of choices made now on options later, issues pertaining to the transfer of this kind of technology, potential impacts on Nucleon's firm culture, and the impact on long-term future of the company.
ii) Does the biotech industry have a value creation problem or a value capture problem? Discuss based on the theories that we have covered in this class and in other classes that you have taken.
iii) How and why do the predictions of the Nucleon case differ from the "reality" discussed in the article "Can Science is a business?